Table 2.
Multivariate analyses for survival of clinical and pathological risk factors and DPD tumour expression in 5-fluorouracil with folinic acid and gemcitabine-treated arms
| Multivariate Analysis | |||||||
|---|---|---|---|---|---|---|---|
| Variable | 5-fluorouracil /folinic acid (n = 115) | Gemcitabine (n = 123) | |||||
| HR (95% CI) | Wald χ2 | p | HR (95% CI) | Wald χ2 | p | ||
| Country | 6.55 | 0.050 | Not included | ||||
| Resection margin | Negative | 1 | 7.75 | 0.005 | 1 | 0.30 | 0.585 |
| Positive | 1.95 (1.22–3.11) | 1.12 (0.75–1.67) | |||||
| WHO | 0 | 1 | 8.47 | 0.013 | 1 | 3.38 | 0.184 |
| 1 | 2.15 (1.28–3.60) | 1.47 (0.95–2.27) | |||||
| 2 | 1.72 (0.76–3.89) | 1.06 (0.53–2.13) | |||||
| Lymph node status | Negative | 1 | 8.94 | 0.003 | 1 | 3.76 | 0.053 |
| Positive | 2.88 (1.44–5.77) | 1.71 (0.99–2.95) | |||||
| DPD expression | 0/1 | 1 | 17.71 | <0.001 | 1 | 3.41 | 0.065 |
| 2/3 | 3.30 (1.89–5.77) | 1.62 (0.97–2.69) | |||||